Inozyme Pharma, Inc. (NASDAQ:INZY – Get Free Report) has been given a consensus rating of “Buy” by the seven research firms that are currently covering the firm, Marketbeat reports. Seven investment analysts have rated the stock with a buy rating. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $16.14.
A number of brokerages recently issued reports on INZY. Stifel Nicolaus began coverage on shares of Inozyme Pharma in a research report on Thursday, September 12th. They set a “buy” rating and a $16.00 price target for the company. Jefferies Financial Group reiterated a “buy” rating and set a $17.00 target price (up from $16.00) on shares of Inozyme Pharma in a report on Tuesday, August 13th. HC Wainwright restated a “buy” rating and issued a $14.00 price target on shares of Inozyme Pharma in a research note on Thursday, August 8th. Wedbush reaffirmed an “outperform” rating and set a $15.00 price objective on shares of Inozyme Pharma in a research report on Monday. Finally, Needham & Company LLC reiterated a “buy” rating and set a $23.00 price objective on shares of Inozyme Pharma in a research note on Tuesday, August 6th.
View Our Latest Report on INZY
Hedge Funds Weigh In On Inozyme Pharma
Inozyme Pharma Stock Down 4.0 %
Shares of NASDAQ:INZY opened at $5.02 on Wednesday. The firm has a market capitalization of $310.52 million, a P/E ratio of -3.66 and a beta of 1.52. The company has a debt-to-equity ratio of 0.48, a quick ratio of 9.84 and a current ratio of 9.84. The stock has a 50 day moving average price of $5.25 and a 200-day moving average price of $5.12. Inozyme Pharma has a 52-week low of $2.69 and a 52-week high of $7.80.
Inozyme Pharma (NASDAQ:INZY – Get Free Report) last posted its quarterly earnings data on Tuesday, August 6th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.07). As a group, equities research analysts anticipate that Inozyme Pharma will post -1.68 EPS for the current fiscal year.
About Inozyme Pharma
Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.
Read More
- Five stocks we like better than Inozyme Pharma
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Why Lennar Stock Could Be the Best Play in the Housing Market
- 3 Stocks to Consider Buying in October
- 2 Energy Stocks Fueling the AI Datacenter Boom
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Receive News & Ratings for Inozyme Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inozyme Pharma and related companies with MarketBeat.com's FREE daily email newsletter.